Loading stock data…
SAN.PA
€79.75-0.97 (-1.21%)
Market OpenUpdated 8:12 AM EDT
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanofi in the Healthcare sector is trading at €79.72. The stock is currently 19% below its 52-week high of €98.36, remaining 3.3% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why SAN.PA maintains its current current market pressure. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price€79.75
Potential Downside
3.6%
Whystock Fair Value€76.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean target€97.36+22.1%
Range€82.00 – €112.00
Fundamentals
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€97.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Strong income play. Yield provides a meaningful total return floor.
510.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.65%
Volume
Today's trading volume
344,626
Recent News
Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness
If you are wondering whether Sanofi at around €80.08 is a bargain or a value trap, you are in the right place to unpack what that price really reflects. The share price has seen a 2.4% decline over the last 7 days, 2.3% over the last 30 days, and sits 2.7% lower year to date, with a 9.5% decline over 1 year and a total return of 11.8% over 5 years. Recent headlines around Sanofi have focused on the broader pharmaceuticals sector, regulatory developments, and shifting investor attention...
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields.
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.
Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead
We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Novavax, Inc. tops our list of the most undervalued stocks. TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy rating. The update reflected expectations that ongoing […]
Company News for Apr 24, 2026
Companies In The Article Are: HON,SNY, R and KDP